154 related articles for article (PubMed ID: 38769311)
1. CDK9 inhibition as an effective therapy for small cell lung cancer.
Valdez Capuccino L; Kleitke T; Szokol B; Svajda L; Martin F; Bonechi F; Krekó M; Azami S; Montinaro A; Wang Y; Nikolov V; Kaiser L; Bonasera D; Saggau J; Scholz T; Schmitt A; Beleggia F; Reinhardt HC; George J; Liccardi G; Walczak H; Tóvári J; Brägelmann J; Montero J; Sos ML; Őrfi L; Peltzer N
Cell Death Dis; 2024 May; 15(5):345. PubMed ID: 38769311
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.
Rajput S; Khera N; Guo Z; Hoog J; Li S; Ma CX
Oncotarget; 2016 Aug; 7(35):56864-56875. PubMed ID: 27486754
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of dinaciclib and CAN508 hybrids as CDK inhibitors.
Odeh DM; Allam HA; Baselious F; Mahmoud WR; Odeh MM; Ibrahim HS; Abdel-Aziz HA; Mohammed ER
Drug Dev Res; 2024 May; 85(3):e22193. PubMed ID: 38685605
[TBL] [Abstract][Full Text] [Related]
4. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
[TBL] [Abstract][Full Text] [Related]
5. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1.
Lemke J; von Karstedt S; Abd El Hay M; Conti A; Arce F; Montinaro A; Papenfuss K; El-Bahrawy MA; Walczak H
Cell Death Differ; 2014 Mar; 21(3):491-502. PubMed ID: 24362439
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
[TBL] [Abstract][Full Text] [Related]
7. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
Saqub H; Proetsch-Gugerbauer H; Bezrookove V; Nosrati M; Vaquero EM; de Semir D; Ice RJ; McAllister S; Soroceanu L; Kashani-Sabet M; Osorio R; Dar AA
Sci Rep; 2020 Oct; 10(1):18489. PubMed ID: 33116269
[TBL] [Abstract][Full Text] [Related]
8. Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis.
Bates DJ; Salerni BL; Lowrey CH; Eastman A
Cancer Biol Ther; 2011 Aug; 12(4):314-25. PubMed ID: 21768777
[TBL] [Abstract][Full Text] [Related]
9. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity.
Chen Z; Wang Z; Pang JC; Yu Y; Bieerkehazhi S; Lu J; Hu T; Zhao Y; Xu X; Zhang H; Yi JS; Liu S; Yang J
Sci Rep; 2016 Jul; 6():29090. PubMed ID: 27378523
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.
Feldmann G; Mishra A; Bisht S; Karikari C; Garrido-Laguna I; Rasheed Z; Ottenhof NA; Dadon T; Alvarez H; Fendrich V; Rajeshkumar NV; Matsui W; Brossart P; Hidalgo M; Bannerji R; Maitra A; Nelkin BD
Cancer Biol Ther; 2011 Oct; 12(7):598-609. PubMed ID: 21768779
[TBL] [Abstract][Full Text] [Related]
11. CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.
Gregory GP; Hogg SJ; Kats LM; Vidacs E; Baker AJ; Gilan O; Lefebure M; Martin BP; Dawson MA; Johnstone RW; Shortt J
Leukemia; 2015 Jun; 29(6):1437-41. PubMed ID: 25578475
[No Abstract] [Full Text] [Related]
12. Dinaciclib potently suppresses MCL-1 and selectively induces the cell death in human iPS cells without affecting the viability of cardiac tissue.
Alsayegh K; Matsuura K; Sekine H; Shimizu T
Sci Rep; 2017 Mar; 7():45577. PubMed ID: 28361959
[TBL] [Abstract][Full Text] [Related]
13. Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells.
Buzzetti M; Morlando S; Solomos D; Mehmood A; Cox AWI; Chiesa M; D'Alessandra Y; Garofalo M; Topham CH; Di Leva G
Sci Rep; 2021 Mar; 11(1):5374. PubMed ID: 33686114
[TBL] [Abstract][Full Text] [Related]
14. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
15. Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.
Danilov AV; Hu S; Orr B; Godek K; Mustachio LM; Sekula D; Liu X; Kawakami M; Johnson FM; Compton DA; Freemantle SJ; Dmitrovsky E
Mol Cancer Ther; 2016 Nov; 15(11):2758-2766. PubMed ID: 27550941
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib.
Hallaj S; Heydarzadeh Asl S; Alian F; Farshid S; Eshaghi FS; Namdar A; Atyabi F; Masjedi A; Hallaj T; Ghorbani A; Ghalamfarsa G; Sojoodi M; Jadidi-Niaragh F
Life Sci; 2020 Oct; 259():118150. PubMed ID: 32726663
[TBL] [Abstract][Full Text] [Related]
17. A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies.
Phillips DC; Jin S; Gregory GP; Zhang Q; Xue J; Zhao X; Chen J; Tong Y; Zhang H; Smith M; Tahir SK; Clark RF; Penning TD; Devlin JR; Shortt J; Hsi ED; Albert DH; Konopleva M; Johnstone RW; Leverson JD; Souers AJ
Leukemia; 2020 Jun; 34(6):1646-1657. PubMed ID: 31827241
[TBL] [Abstract][Full Text] [Related]
18. Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung.
Wang WZ; Shilo K; Amann JM; Shulman A; Hojjat-Farsangi M; Mellstedt H; Schultz J; Croce CM; Carbone DP
Cell Death Dis; 2021 Jun; 12(6):577. PubMed ID: 34088900
[TBL] [Abstract][Full Text] [Related]
19. Overview of CDK9 as a target in cancer research.
Morales F; Giordano A
Cell Cycle; 2016; 15(4):519-27. PubMed ID: 26766294
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression.
Lochmann TL; Floros KV; Naseri M; Powell KM; Cook W; March RJ; Stein GT; Greninger P; Maves YK; Saunders LR; Dylla SJ; Costa C; Boikos SA; Leverson JD; Souers AJ; Krystal GW; Harada H; Benes CH; Faber AC
Clin Cancer Res; 2018 Jan; 24(2):360-369. PubMed ID: 29118061
[No Abstract] [Full Text] [Related]
[Next] [New Search]
